Repros Therapeutics Inc. (NASDAQ:RPRX) on Oct. 21 reported results from a large, controlled, long-term safety study comparing Androxal(R) to a placebo. In this study of Androxal(R), ZA-303, no new safety signals were identified, including no evidence of negative effects on bone mineral density. Over 79% of the Androxal(R)-treated subjects had morning testosterone levels above 300 ng/dL after being treated for 12 months. Repros Therapeutics Inc. … Continue reading Morning Alert: Repros Therapeutics Inc. (NASDAQ:RPRX), Hewlett-Packard Company (NYSE:HPQ), Flowers Foods, Inc. (NYSE:FLO), American River Bankshares (NASDAQ:AMRB), Delta Air Lines, Inc. (NYSE:DAL)